Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)

Biomarkers. 2017 May-Jun;22(3-4):261-267. doi: 10.1080/1354750X.2016.1204003. Epub 2016 Jul 12.

Abstract

Context and objective: To evaluate if YKL-40 can provide prognostic information in patients with ischemic heart failure (HF) and identify patients who may benefit from statin therapy.

Materials and methods: The association between serum YKL-40 and predefined outcome was evaluated in 1344 HF patients assigned to rosuvastatin or placebo.

Results: YKL-40 was not associated with outcome in adjusted analysis. In YKL-40 tertile 1, an effect on the primary outcome (HR 0.50, p = 0.006) and CV death (HR 0.54, p = 0.040) was seen by rosuvastatin in adjusted analysis.

Conclusions: A beneficial modification of outcome was observed with statin therapy in patients with low YKL-40 levels.

Keywords: Heart failure; YKL-40; mortality; risk prediction.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Aged
  • Chitinase-3-Like Protein 1 / blood*
  • Chronic Disease
  • Female
  • Heart Failure / blood
  • Heart Failure / diagnosis
  • Heart Failure / drug therapy*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Predictive Value of Tests
  • Prognosis
  • Rosuvastatin Calcium / therapeutic use*
  • Treatment Outcome

Substances

  • CHI3L1 protein, human
  • Chitinase-3-Like Protein 1
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Rosuvastatin Calcium